Table 2.

Cox proportional hazards regression models for OS and PFS in the entire study population according to organ-specific irAEs

Organ-specific irAEs	OS				PFS
	Univariable model		Multivariable model		Univariable model		Multivariable model
	HR (95% CI)	P value	HR (95% CI)	P value	HR (95% CI)	P value	HR (95% CI)	P value
Gastrointestinal	1.15 (0.80 to 1.65)	0.438	1.33 (0.87 to 2.03)	0.189	1.27 (0.94 to 1.72)	0.113	1.30 (0.92 to 1.84)	0.141
Skin	0.84 (0.44 to 1.61)	0.601	1.16 (0.64 to 2.11)	0.628	1.49 (0.96 to 2.31)	0.078	1.81 (1.18 to 2.27)	0.006
Endocrine	0.46 (0.24 to 0.88)	0.019	0.43 (0.21 to 0.89)	0.023	0.78 (0.51 to 1.17)	0.223	0.76 (0.50 to 1.16)	0.207
Pneumonitis	1.92 (0.97 to 3.84)	0.063	1.41 (0.73 to 2.72)	0.304	1.78 (0.88 to 3.60)	0.108	1.50 (0.76 to 2.97)	0.241
Neurological	1.39 (0.87 to 2.22)	0.163	1.64 (1.03 to 2.60)	0.036	1.28 (0.80 to 2.04)	0.296	1.63 (1.04 to 2.56)	0.032
Musculoskeletal	0.29 (0.08 to 1.08)	0.066	0.22 (0.06 to 0.88)	0.032	0.79 (0.44 to 1.44)	0.449	0.56 (0.28 to 1.11)	0.098
Liver	1.38 (1.02 to 1.86)	0.034	1.53 (1.11 to 2.10)	0.009	1.38 (1.06 to 1.80)	0.018	1.52 (1.15 to 2.01)	0.004
Renal	1.20 (0.56 to 2.54)	0.641	1.19 (0.52 to 2.70)	0.683	1.02 (0.48 to 2.15)	0.960	1.02 (0.45 to 2.30)	0.958
Other	1.25 (0.62 to 2.54)	0.537	1.15 (0.57 to 2.32)	0.701	1.42 (0.77 to 2.60)	0.258	1.45 (0.79 to 2.66)	0.225

P values <0.05 are highlighted in bold

irAEs, immune-related adverse events; OS, overall survival; PFS, progression-free survival.